Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

(GPAT Trial)

This trial tests the safety and feasibility of using psilocybin, a psychedelic substance, in a group therapy setting to help individuals with post-traumatic stress disorder (PTSD). The goal is to determine if this treatment can reduce the severity of PTSD symptoms. The trial specifically seeks veterans, first responders, female survivors of sexual violence, or Indigenous people who have experienced moderate to severe PTSD for at least six months. Participants must attend group sessions and adhere to the study's requirements. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial may require you to stop taking certain medications that could interfere with psilocybin. If needed, you must be willing to taper off and discontinue these medications.

A previous study found psilocybin to be safe and well-tolerated for people with PTSD. Research suggests that psilocybin, often used to treat depression, might also be safe for PTSD. Some reports indicate that a single dose, combined with therapy, was well-tolerated and did not cause serious side effects. However, since this trial is in an early stage, researchers are still collecting safety data. Early trials focus on ensuring the treatment's safety for participants. While some evidence supports its safety, further research is needed to confirm these findings.¹²³⁴⁵

Researchers are excited about psilocybin-assisted therapy for PTSD because it represents a novel approach compared to standard treatments like SSRIs or cognitive behavioral therapy. Unlike these treatments, psilocybin, a compound found in certain mushrooms, is believed to work by promoting new neural connections and altering perception, which can help patients process traumatic memories differently. This could lead to rapid and profound changes in mood and cognition, offering hope for faster and potentially more effective relief from PTSD symptoms.

Research has shown that psilocybin, the investigational treatment in this trial, combined with group therapy, may help reduce PTSD symptoms. Early data suggest that even one dose can improve symptoms for some individuals. Patients have reported feeling better and more connected to the world after treatment. Recent studies emphasize the safety and potential of psilocybin for treating mental health issues like PTSD. While more research is needed, these early findings offer promise for those considering this treatment.³⁵⁶⁷⁸